Sanofi

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Sanofi and buy or sell other stocks, ETFs, and their options commission-free!

About SNY

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines, vaccines franchises, support, and corporate functions 1973 and is headquartered in Paris, France. 

CEO
Belén Garijo López
CEOBelén Garijo López
Employees
76,493
Employees76,493
Headquarters
Paris, Ile-de-France
HeadquartersParis, Ile-de-France
Founded
1973
Founded1973
Employees
76,493
Employees76,493

SNY Key Statistics

Market cap
111.64B
Market cap111.64B
Price-Earnings ratio
24.17
Price-Earnings ratio24.17
Dividend yield
3.75%
Dividend yield3.75%
Average volume
3.42M
Average volume3.42M
High today
$46.61
High today$46.61
Low today
$44.93
Low today$44.93
Open price
$46.44
Open price$46.44
Volume
5.52M
Volume5.52M
52 Week high
$50.61
52 Week high$50.61
52 Week low
$39.07
52 Week low$39.07

SNY News

Seeking Alpha 7h
Insmed may be worth $170 to $210 a share in takeover, analyst

Insmed (INSM) may be worth $170-$210 a share in a takeover after a report that Sanofi (SNY) is weighing a purchase of the drugmaker, according to an RBC analyst...

Insmed may be worth $170 to $210 a share in takeover, analyst
TipRanks 7h
Insmed deal makes ‘considerable strategic sense’ for Sanofi, says BMO Capital

After Bloomberg reported that Sanofi (SNY) is evaluating a potential acquisition of Insmed (INSM), BMO Capital analyst Conor MacKay argued that adding Insmed’s...

Benzinga 7h
With Dupixent's Patent Clock Ticking, Sanofi Circles Insmed

Insmed Inc. (NASDAQ:INSM) stock surged Thursday following a report that French pharmaceutical giant Sanofi SA (NASDAQ:SNY) is exploring a potential acquisition...

With Dupixent's Patent Clock Ticking, Sanofi Circles Insmed

Analyst ratings

60%

of 10 ratings
Buy
60%
Hold
40%
Sell
0%

More SNY News

Investor's Business Daily 7h
Sanofi Reportedly Gears Up For The Biggest Biotech Deal In Years

Technology Sanofi Reportedly Gears Up For The Biggest Biotech Deal In Years Licensing Insmed (INSM) stock surged Thursday on a rumored takeover bid from French...

Sanofi Reportedly Gears Up For The Biggest Biotech Deal In Years
TipRanks 11h
Sanofi eyeing takeover of U.S. drugmaker Insmed, Bloomberg reports

Sanofi (SNY) is exploring a potential acquisition of U.S. drugmaker Insmed (INSM), which could rank among the largest biopharma deals in recent years, Bloomberg...

Benzinga 12h
Dual Regulatory Wins for Sanofi Bring New Oral Gaucher Therapy and Upgraded Rabies Shot

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Sanofi SA’s (NASDAQ:SNY) Infilbray (venglustat), a novel, oral glucosylceramide synthase inhi...

Dual Regulatory Wins for Sanofi Bring New Oral Gaucher Therapy and Upgraded Rabies Shot
Benzinga 12h
Jacobs Scores Key Role in Sanofi's New Insulin Factory in Germany - Sanofi, Jacobs Solutions - Benzinga

...

Jacobs Scores Key Role in Sanofi's New Insulin Factory in Germany - Sanofi, Jacobs Solutions - Benzinga
TipRanks 15h
Jacobs selected by Sanofi as EPCM partner for new insulin manufacturing facility

Jacobs (J) has been selected by Sanofi (SNY) as the engineering, procurement and construction management, or EPCM, partner for a new insulin manufacturing facil...

Seeking Alpha 16h
Jacobs tapped by Sanofi for Frankfurt insulin facility

Jacobs tapped by Sanofi for Frankfurt insulin facility Nov 19, 2026, 5:03 AM ET Sanofi (SNY) Stock, J Stock By : Arundhati Sarkar, SA News Editor Recommended Fo...

Jacobs tapped by Sanofi for Frankfurt insulin facility
Seeking Alpha 1d
Sanofi wins approval of venglustat for Gaucher disease

Sanofi wins approval of venglustat for Gaucher disease Nov 18, 2026, 5:43 PM ET Sanofi (SNY) Stock SAN:CA By : Jonathan Block, SA News Editor The US FDA approve...

Sanofi wins approval of venglustat for Gaucher disease

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.